Medigen Biotech

Medigen Biotechnology Corp. is a Taiwan-based biopharmaceutical company focused on the development of novel therapies for liver diseases and cancer. The company's core business spans drug development, molecular diagnostics, and cell therapy, with a significant emphasis on addressing unmet medical needs in the Asia-Pacific region. Medigen is well-known for its development of PI-88, a first-in-class heparanase inhibitor for liver cancer, and its expansion into personalized medicine through its diagnostic subsidiaries. Additionally, the company has established a strong presence in the vaccine market through its subsidiary, Medigen Vaccine Biologics Corp, which developed a prominent COVID-19 vaccine. Medigen continues to advance its pipeline in oncology and infectious diseases while maintaining a robust manufacturing and diagnostic infrastructure.